What is NeoGenomics's R&D?

NeoGenomics (NEO) reported R&D of $9.53M in Q1 2026.

How has NeoGenomics's R&D changed year-over-year?

NeoGenomics's R&D decreased by 6.4% year-over-year, from $10.18M to $9.53M.

What is the long-term trend for NeoGenomics's R&D?

Over 4 years (2021 to 2025), NeoGenomics's R&D has grown at a 14.1% compound annual growth rate (CAGR), from $21.87M to $37.08M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

NeoGenomics NEO R&D

R&D at other companies

Personalis, Inc.PSNL

$14.54M+15.0%

Guardant HealthGH

$91.04M+2.8%

Natera, Inc.NTRA

$210.7M+63.2%

Tempus AI, Inc.TEM

$48.24M+34.5%

GeneDx HoldingsWGS

$19.8M+57.5%

Opko HealthOPK

$29.2M-5.3%

Segments

By segment

See full

Reportable Segment$8.46M-7.1%

Other financials

Income statement

See full

Revenue$186.7M+11.1%

Gross profit$80.9M+10.4%

Operating income-$18.2M+34.4%

Net income-$17.1M+34.0%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$146.1M-57.8%

Total debt$66.3M+5.3%

Total equity$828.8M-6.7%

Total assets$1.3B-15.9%

Cash flow

See full

Operating cash flow-$8.1M+67.9%

CapEx$5.0M+11.1%

Free cash flow-$13.1M+56.0%

Valuation

See full

Market cap$1.68B+86.5%

Enterprise value$1.6B+159%

P/S2.3×+0.9×

Profitability

See full

Gross margin43.2%-1.1pp

Operating margin-14.2%+1.1pp

Net margin-13.3%+2.4pp

FCF margin-4.9%—

Returns & leverage

See full

Return on equity-11.6%+6.2pp

Debt / equity0.1×0.0×

Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NeoGenomics's R&D?: NeoGenomics (NEO) reported R&D of $9.53M in Q1 2026.
How has NeoGenomics's R&D changed year-over-year?: NeoGenomics's R&D decreased by 6.4% year-over-year, from $10.18M to $9.53M.
What is the long-term trend for NeoGenomics's R&D?: Over 4 years (2021 to 2025), NeoGenomics's R&D has grown at a 14.1% compound annual growth rate (CAGR), from $21.87M to $37.08M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.